针对 COVID-19 引发的 ARDS 的炎症小体抑制剂的潜在治疗影响。
Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS.
机构信息
Advanced Medical Pharma (BIOTEC), Benevento, Italy.
Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
出版信息
Curr Med Chem. 2023;30(12):1406-1419. doi: 10.2174/0929867329666220906111550.
Given the importance of COVID-19-induced ARDS, recently, researchers have strived to determine underlying mechanisms involved in the inflammatory responses. In this regard, inflammasomes possess a distinct priority for cytokine storm occurrence and, subsequently, ARDS progression in ill patients with SARS-CoV-2 infection. In this minireview, the characteristics of known inflammasome inhibitors and designed research in this field were concretely deciphered.
鉴于 COVID-19 引起的 ARDS 的重要性，最近，研究人员一直在努力确定炎症反应中涉及的潜在机制。在这方面，炎症小体在发生细胞因子风暴方面具有明显的优先级，随后在感染 SARS-CoV-2 的 SARS 患者中导致 ARDS 的进展。在这篇迷你综述中，具体破译了已知炎症小体抑制剂的特征和该领域的设计研究。
Zotero 插件